PMID- 36947773
OWN - NLM
STAT- MEDLINE
DCOM- 20230324
LR  - 20230324
IS  - 2326-6929 (Electronic)
IS  - 0011-4162 (Linking)
VI  - 111
IP  - 1
DP  - 2023 Jan
TI  - Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related 
      Intertriginous and Flexural Exanthema: Should You Discontinue the Offending 
      Agent?
PG  - 18-21
LID - 10.12788/cutis.0681 [doi]
AB  - Epidermal growth factor receptor (EGFR) inhibitors cause numerous cutaneous 
      adverse events (AEs), including papulopustular eruptions, paronychia, acral 
      fissures, xerosis, alopecia, and trichomegaly. Symmetrical drug-related 
      intertriginous and flexural exanthema (SDRIFE) is a cutaneous reaction that has 
      been uncommonly reported in association with EGFR inhibitors, though the optimal 
      management strategy for this condition is unknown. We present 2 cases of SDRIFE 
      secondary to EGFR inhibitor therapy in which the EGFR inhibitor was successfully 
      continued while topical therapy was administered for effective control of 
      symptoms. We also review the literature on EGFR inhibitor-related SDRIFE to 
      assess the range of approaches to treating this condition. Our analysis suggests 
      that the dermatologist is critical in diagnosing and treating this cutaneous AE, 
      which may be supported with skin-directed therapy and may not require 
      discontinuation of cancer treatment.
FAU - Lewis, William
AU  - Lewis W
AD  - Department of Dermatology, University of Pennsylvania, Philadelphia.
FAU - Forrestel, Amy
AU  - Forrestel A
AD  - Department of Dermatology, University of Pennsylvania, Philadelphia.
FAU - Baumrin, Emily
AU  - Baumrin E
AD  - Department of Dermatology, University of Pennsylvania, Philadelphia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Humans
MH  - *Exanthema/chemically induced/diagnosis/complications
MH  - *Drug Eruptions/diagnosis/etiology
MH  - Skin
MH  - Administration, Cutaneous
MH  - ErbB Receptors
EDAT- 2023/03/23 06:00
MHDA- 2023/03/25 06:00
CRDT- 2023/03/22 16:32
PHST- 2023/03/22 16:32 [entrez]
PHST- 2023/03/23 06:00 [pubmed]
PHST- 2023/03/25 06:00 [medline]
AID - cutis.0681 [pii]
AID - 10.12788/cutis.0681 [doi]
PST - ppublish
SO  - Cutis. 2023 Jan;111(1):18-21. doi: 10.12788/cutis.0681.